[Federal Register Volume 89, Number 171 (Wednesday, September 4, 2024)]
[Notices]
[Page 71878]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-19718]


 ========================================================================
 Notices
                                                 Federal Register
 ________________________________________________________________________
 
 This section of the FEDERAL REGISTER contains documents other than rules 
 or proposed rules that are applicable to the public. Notices of hearings 
 and investigations, committee meetings, agency decisions and rulings, 
 delegations of authority, filing of petitions and applications and agency 
 statements of organization and functions are examples of documents 
 appearing in this section.
 
 ========================================================================
 

  Federal Register / Vol. 89, No. 171 / Wednesday, September 4, 2024 / 
Notices  

[[Page 71878]]



AGENCY FOR INTERNATIONAL DEVELOPMENT


Notice of Closed Malaria Vaccine Development Program Scientific 
Advisory Committee Meeting

AGENCY: Agency for International Development (USAID).

ACTION: Notice of closed Federal advisory committee meeting.

-----------------------------------------------------------------------

SUMMARY: USAID is publishing this notice to announce a closed meeting 
of the USAID Malaria Vaccine Development Program (MVDP) Scientific 
Advisory Committee (SAC).

DATES: The meeting will be held Tuesday, October 22, 2024, from 8:00 
a.m. to 5:30 p.m. Eastern Daylight Time (EDT) and Wednesday, October 
23, 2024, from 8:00 a.m. to 3:00 p.m. EDT.

ADDRESSES: The closed meeting will be held at 455 Massachusetts Avenue 
NW, Suite 1000, Washington, DC 20001.

FOR FURTHER INFORMATION CONTACT: Email: [email protected], 
or Susan Youll, Designated Federal Officer, 202-712-4300 (Voice). 
Mailing address is: USAID, 1300 Pennsylvania Ave NW, Washington, DC.

SUPPLEMENTARY INFORMATION: 
    Purpose of the Meeting: The MVDP SAC will consult with, provide 
information to, and advise USAID on matters and issues relating to 
malaria vaccine development, scientific technologies, and any other 
related matters. The SAC will provide broad scientific review of USAID 
MVDP activities and investments to ensure MVDP focus and coherence, and 
to ensure the application of the highest standards of technical and 
scientific excellence.
    Background: The SAC consists of no more than 13 members with 
demonstrated technical expertise and experience in areas related to 
malaria vaccine development, including, but not limited to: vaccine 
development, immunology, malariology, structural biology, preclinical 
animal models, regulatory affairs, and clinical research. These 
individuals may include, but not be limited to, employees of 
international organizations involved in vaccine development, academic 
institutions, pharmaceutical or biotechnology companies, and other U.S. 
government agencies. The members will be selected to represent diverse 
points of view and appointments will be made free from all forms of 
discrimination. The members are appointed by the US Global Malaria 
Coordinator.
    As stated in its charter, the SAC's role is to:
    (a) review written updates provided by the MVDP and their partners;
    (b) receive presentations with data and progress from the last 
meeting and any strategy changes from MVDP staff and partners,
    (c) discuss data and ask questions of MVDP staff and partners 
regarding presentations;
    (d) submit a meeting report that may:
     provide strategic advice and scientific guidance;
     include recommendations on overall program strategy; and,
     identify new research and development opportunities that 
support MVDP objectives.
    MVDP SAC meetings are held approximately once a year. More 
information USAID's Malaria Vaccine Development Program is available 
at: https://www.usaid.gov/global-health/health-areas/malaria/research-innovation/malaria-vaccine-development-program-mvdp.

Closed Meeting Exemption and Determination

    This meeting is being held under the provisions of chapter 10 of 
title 5, United States Code (U.S.C.) (commonly known as the ``Federal 
Advisory Committee Act'' or ``FACA'') and 5 U.S.C. 552b (commonly known 
as the ``Government in the Sunshine Act'').
    The exemption is authorized by section 10(d) of the FACA, which 
permits the closure of advisory committee meetings, or portions 
thereof, if the head of the agency to which the advisory committee 
reports determines such meetings may be closed to the public in 
accordance with subsection (c) of the Government in the Sunshine Act (5 
U.S.C. 552b(c)). In this case, the applicable provisions of 5 U.S.C. 
552b(c) are subsection 552b(c)(4), which permits closure to protect 
information that would disclose confidential trade secrets or 
commercial property such as patentable material.
    The Administrator, on April 9, 2024, delegated authority to close 
MVDP SAC meetings to the public, to the U.S. Global Malaria 
Coordinator. The Global Malaria Coordinator, with the concurrence of 
the General Counsel, formally determined on August, 27, 2024, pursuant 
to section 10 of the FACA, (5 U.S.C. 1009(d)), that the MVDP SAC 
meeting shall be exempt from the provisions relating to public meetings 
found in 5 U.S.C. 1009(a)(1) and 1009(a)(3).

Susan Youll,
USAID Designated Federal Officer for the MVDP SAC, Global Health 
Bureau, U.S. Agency for International Development.
[FR Doc. 2024-19718 Filed 9-3-24; 8:45 am]
BILLING CODE 6116-01-P